Cost-effectiveness of blinatumomab versus salvage chemotherapy in relapsed or refractory Philadelphia-chromosome-negative B-precursor acute lymphoblastic leukemia from a US payer perspective-Reference-Cited by-同舟云学术

Cost-effectiveness of blinatumomab versus salvage chemotherapy in relapsed or refractory Philadelphia-chromosome-negative B-precursor acute lymphoblastic leukemia from a US payer perspective

Published:2017-07-11 Issue:9 Volume:20 Page:911-922
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Delea Thomas E.¹,Amdahl Jordan¹,Boyko Diana¹,Hagiwara May¹,Zimmerman Zachary F.²,Franklin Janet L.²,Cong Ze³,Hechmati Guy²,Stein Anthony⁴

Affiliation:

1. Policy Analysis Inc. (PAI), Brookline, MA, USA;

2. Global Development, Amgen Inc., Thousand Oaks, CA, USA;

3. Global Health Economics, Amgen Inc., South San Francisco, CA, USA;

4. City of Hope, Department of Hematology and Hematopoietic Cell Transplantation, Duarte, CA, USA

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2017.1344127

Reference38 articles.

1. A population-based cytogenetic study of adults with acute lymphoblastic leukemia

2. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study

3. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia

4. Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group

5. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. THE COST OF ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT IN CHILDREN USING COMBINED CHEMOTHERAPY AND IMMUNOTHERAPY: COMPARISON OF ESTIMATED AND REAL VALUES;Acta medica Eurasica;2024-03-28

2. Real-world use of inotuzumab ozogamicin is associated with lower health care costs than blinatumomab in patients with acute lymphoblastic leukemia in the first relapsed/refractory setting;Journal of Comparative Effectiveness Research;2024-02

3. Optimal assessment share structured of Pharmacoeconomics for medical drugs according to minimax criterion;PHARM PRACT-GRANADA;2024

4. Estimating the Lifetime Medical Cost Burden of an Allogeneic Hematopoietic Cell Transplantation Patient;Transplantation and Cellular Therapy;2023-10

5. Evaluating blinatumomab implementation in low- and middle-income countries: a study protocol;Implementation Science Communications;2022-06-11